PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.75%
Negative revenue growth while AVGO stands at 4.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.29%
Negative gross profit growth while AVGO is at 4.94%. Joel Greenblatt would examine cost competitiveness or demand decline.
-0.24%
Negative EBIT growth while AVGO is at 7.41%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
0.24%
Operating income growth under 50% of AVGO's 7.41%. Michael Burry would be concerned about deeper cost or sales issues.
9.66%
Net income growth under 50% of AVGO's 33.33%. Michael Burry would suspect the firm is falling well behind a key competitor.
11.27%
EPS growth under 50% of AVGO's 33.33%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
8.45%
Diluted EPS growth under 50% of AVGO's 32.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.01%
Share reduction while AVGO is at 1.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.59%
Reduced diluted shares while AVGO is at 1.21%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
8.09%
Dividend growth of 8.09% while AVGO is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-6.68%
Negative OCF growth while AVGO is at 58.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.76%
FCF growth under 50% of AVGO's 62.61%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
72.41%
10Y revenue/share CAGR above 1.5x AVGO's 13.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
34.31%
5Y revenue/share CAGR above 1.5x AVGO's 13.16%. David Dodd would look for consistent product or market expansions fueling outperformance.
16.04%
3Y revenue/share CAGR 1.25-1.5x AVGO's 13.16%. Bruce Berkowitz might see better product or regional expansions than the competitor.
177.75%
10Y OCF/share CAGR above 1.5x AVGO's 68.33%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
85.39%
5Y OCF/share CAGR 1.25-1.5x AVGO's 68.33%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
1.19%
3Y OCF/share CAGR under 50% of AVGO's 68.33%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
120.11%
Below 50% of AVGO's 705.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
96.83%
Below 50% of AVGO's 705.69%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
46.06%
Below 50% of AVGO's 705.69%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
22.64%
Below 50% of AVGO's 70.62%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
19.66%
Below 50% of AVGO's 70.62%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
22.49%
Below 50% of AVGO's 70.62%. Michael Burry suspects a serious short-term disadvantage in building book value.
511.63%
Dividend/share CAGR of 511.63% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
336.24%
Dividend/share CAGR of 336.24% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
29.79%
3Y dividend/share CAGR of 29.79% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-13.45%
Firm’s AR is declining while AVGO shows 2.15%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
6.74%
Inventory growth well above AVGO's 2.16%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.95%
Asset growth well under 50% of AVGO's 12.34%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.84%
50-75% of AVGO's 11.50%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-6.00%
Our R&D shrinks while AVGO invests at 5.63%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.26%
We cut SG&A while AVGO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.